Uprevstobart
- Generic Name
- Uprevstobart
Study of INCA 0186 in Subjects With Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Squamous Cell Carcinoma of the Head and Neck (SCCHN)Advanced Solid TumorsGastrointestinal (GI) Malignancies
- Interventions
- First Posted Date
- 2021-08-04
- Last Posted Date
- 2025-05-04
- Lead Sponsor
- Incyte Corporation
- Target Recruit Count
- 57
- Registration Number
- NCT04989387
- Locations
- 🇺🇸
Emory University, Atlanta, Georgia, United States
🇧🇪Universitair Ziekenhuis Antwerpen (Uza), Edegem, Belgium
🇳🇱University Medical Center Groningen, Groningen, Netherlands
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath